Caplyta (lumateperone) receives new indication for bipolar I depression monotherapy
FDA approved lumateperone (Caplyta; Intra-Cellular Therapies) as monotherapy for major depressive episodes associated with bipolar I disorder — expanding the existing bipolar II and adjunctive indications. Lumateperone is a first-in-class dual modulator of serotonin and dopamine pathways. The approval was supported by the LUMINATE-1 trial showing statistically significant improvement on the MADRS total score at week 6 vs placebo.
Caplyta (lumateperone 42 mg) ↗ is a first-in-class atypical antipsychotic that simultaneously modulates serotonin (5-HT2A antagonism), dopamine (D2 partial agonism in striatum, D1 signalling in prefrontal cortex), and glutamate pathways. On 7 October 2026, FDA approved ↗ lumateperone as monotherapy for major depressive episodes associated with bipolar I disorder — adding to existing approvals for bipolar II depression and as adjunctive therapy with lithium or valproate.
About bipolar depression
Bipolar I disorder affects approximately 2.8% of US adults ↗. Depressive episodes are more frequent, longer, and more disabling than manic episodes in most patients. Historically, very few agents have monotherapy approval for bipolar depression — quetiapine, lurasidone, and the olanzapine-fluoxetine combination (OFC) are the others. Most antidepressants carry a risk of precipitating mania when used without a mood stabiliser. Lumateperone's mechanism — acting on multiple receptor systems without strong D2 blockade — was designed to reduce the metabolic and extrapyramidal side effects typical of older antipsychotics.
LUMINATE-1 trial evidence
The approval was supported by the LUMINATE-1 phase 3 randomised controlled trial. Adults with a bipolar I depressive episode were randomised to lumateperone 42 mg once daily or placebo. At week 6, lumateperone showed a statistically significant reduction in the MADRS total score ↗ (Montgomery-Åsberg Depression Rating Scale) vs placebo — the primary endpoint. Secondary endpoints including CGI-BP-S depressive component also favoured lumateperone. The safety profile was consistent with prior trials; somnolence, dizziness, and nausea were the most common adverse effects. Trial registration: ClinicalTrials.gov ↗.
Prescribing notes
Lumateperone 42 mg is taken orally once daily with food. It is metabolised primarily by CYP3A4 ↗ and UGT1A4; dose adjustments are required with strong CYP3A4 inhibitors or inducers. Unlike most antipsychotics, it does not carry a high-risk metabolic profile — weight gain and QTc prolongation were not significant in trials. Full prescribing information is available on DailyMed ↗.
FAQ
What does FDA approval mean?
FDA approval means the agency has determined, based on scientific evidence submitted by the manufacturer, that a drug's benefits outweigh its known risks for a specific indication and patient population. The review process includes evaluation of clinical trial data, manufacturing quality, and proposed labelling. See the FDA drug approval process overview ↗.
Does approval mean the drug is available immediately?
Not always. Commercial launch timelines depend on manufacturing scale-up, pricing, and distribution. REMS-restricted drugs ↗ require prescriber or pharmacy enrolment before the product can be dispensed. Rare disease drugs may also have limited initial supply. Check the manufacturer's website or RxNav ↗ for availability status.